I
t is probable that there are both genetic and environmental risk factors for breast and/or ovarian cancer. Adequate evidence suggests that mutations in the BRCA1 and BRCA2 genes are associated with an increased risk of breast and ovarian cancer, and perhaps other cancers as well (U.S. Preventive Services Task Force, 2013). Although estimates vary widely, in the general population about 5%-10% of all breast cancer and 10%-15% of ovarian cancer cases can be attributed to variation in these genes. This rate is higher in some populations and families (Fackenthal and Olopade, 2007; Ferla et al., 2007) .
Millions of individuals worldwide have a mutation in the BRCA1 or BRCA2 gene. Mutations in one of these genes can significantly increase an individual's chances of developing hereditary breast or ovarian cancer. A positive result asks for difficult decisions from the individual. The individual needs as much validated information as possible to make the best choices from options that are difficult to begin with. Clinicians need to know which mutations have been identified and whether they are putative. Researchers need information about the genes and associated clinical data to help refine the predictive value of the genetic test, potential allele-specific therapies, and further understanding of disease progression. None of this is possible with the mutations alone, but knowing what mutations have been discovered is an important part of discovery and clinical services.
Some genes have substantial variation represented in open databases. Some of these databases have received attention from the Human Variome Project, which seeks to ''collect and curate all human variation affecting human health (Ring et al., 2006) .'' There are groups working on tools to curate the data, such as the Leiden Open Variation Database (LOVD) (Fokkema et al. 2011) , whose goal is to provide an open tool to display DNA variation. LOVD at NCBI (National Center for Biotechnology Information) offers the LOVD system installed on an NCBI server at the National Library of Medicine of the National Institutes of Health. PXE International, a small disease-specific advocacy organization for pseudoxanthoma elasticum (PXE) founded and managed by this author, has created a comprehensive database of mutations using LOVD at NCBI (PXE International, 2013, available at http://pxe.org/mutation-database). The database contains 288 ABCC6 mutations from nearly 500 people representing 20% of the known affected population and almost all of the tested population. With permission from individuals who have been tested, PXE International collects mutations from GeneDx, the laboratory with the largest ABCC6 volume of testing. Individuals from all over the world send in their test results to be placed in the database. In a bygone era, these mutations would be published, but now, unless there are other important considerations, they go largely unpublished. There have been some appeals for ''microattribution'' to encourage crowdsourcing variation for the human genome (Giardine et al., 2013; Patrinos et al., 2012; Giardine et al., 2011; Axton, 2011) , building on a plea Axton made as early as 2008 (Axton, 2008 , Nature Genetics Blog, available at http:// blogs.nature.com/freeassociation/2008/03/microattribution_ for_community_I.html).
In recent years, NCBI has taken on the effort of cataloging variation. ClinVar provides an open-access archive of reports of relationships among clinically important variants and phenotypes. The database is integrated with other NCBI assets: dbSNP and dbVar, which maintain information about the location of variation in the genome (Landrum et al., 2013) . Other efforts include the International Collaboration for Clinical Genomics (ICCG) and an effort newly funded by the National Institutes of Health, called the ClinGen Project, in which a very large consortium of these laboratories will share variants and clinical data.
In June 2013, the BRCA1/2 genes received a great deal of attention. In the lawsuit Association for Molecular Pathology et al. v. Myriad Genetics, Inc., et al, the U.S. Supreme Court determined that isolated genomic DNA is not patent-eligible. This opened the door for many other laboratories to test for BRCA1/2 (Myriad is suing). However, the Supreme Court ruling did nothing to open access to the proprietary BRCA1/2 mutation database, which is considered Myriad's ''trade secret'' and legal according to common business practices. Myriad is not the only testing laboratory that doesn't put all of the variation it discovers into open-access databases.
For variation in all genes, this is unacceptable. clinical data. The steering committee includes many of the brave pioneers from the ICCG and others who have worked on open access for a long time. A list of the steering committee and members of the consortium can be found on the Free the Data Web site (available at www.free-the-data.org).
Free the Data starts with the BRCA1/2 genes, arguably the most sequenced genes in the human genome. The campaign will expand to encompass all genes and all mutations, powering open-access research and better health for all. In the information age, data are not scarce and cannot be treated as a commodity. It is time to Free the Data!
